Stock Market Reviews

Read and share opinions on HURA (TuHURA Biosciences, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market

Latest News

• TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
  Nov 14, 2025
• TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
  Nov 3, 2025
• HURA: IFx-2.0 Phase III Begins
  Aug 21, 2025
• TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
  Aug 20, 2025
• TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
  Aug 14, 2025
• TuHURA Biosciences, Inc.'s (NASDAQ:HURA) last week's 11% decline must have disappointed retail investors who have a significant stake
  Aug 11, 2025
• TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
  Jul 1, 2025
• TuHURA Biosciences Completes Acquisition of Kineta
  Jun 30, 2025
• TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
  Jun 24, 2025
• TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
  Jun 23, 2025
• FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
  Jun 9, 2025
• TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy
  Jun 3, 2025
• TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
  Jun 2, 2025
• HURA: First Quarter 2025 Results
  May 19, 2025
• TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
  May 15, 2025
• TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference
  May 13, 2025
• TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)
  May 5, 2025
• TuHURA Biosciences Reports Cancer Immunotherapy Safe, Well Tolerated in Clinical Trial
  Apr 28, 2025
• TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
  Apr 28, 2025
• Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts?
  Apr 18, 2025